This activity is intended for hematologists/oncologists, pediatric hematologists, pharmacists, nurse practitioners, hematology/oncology nurses, and other healthcare professionals who care for patients with CML.
The goal of this activity is to improve the competence of all members of the interdisciplinary team in applying the latest guidance and clinical data in the management of individuals with chronic myeloid leukemia.
After completing this activity, participants should be better able to:
Compare the mechanisms of actions of available TKIs to block BCR::ABL activity and the associated toxicity profiles of these agents when used to treat patients with CML
Increase patient involvement in the initiation of treatment, monitoring of response, managing toxicity, and optimizing adherence
Select individualized therapy for patients with chronic-phase CML, considering patient goals, age, medical history, comorbidities, risk score, previous CML treatment, and BCR::ABL1 mutation status
Monitor treatment responses and determine optimal timing for therapy changes
Evaluate the available evidence, potential predictive factors, patient preferences, and expert recommendations guiding potential therapy discontinuation and treatment-free remissions
Optimally sequence second-line, third-line, and later therapeutic strategies to overcome resistance after previous TKI failure
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Jorge Cortes, MD: consultant/advisor/speaker: Bristol-Myers Squibb, Kartos, Novartis, Sun Pharma, Takeda; researcher: Kartos, Novartis, Sun Pharma, Takeda.
Neil P. Shah, MD, PhD: consultant/advisor/speaker: Bristol-Myers Squibb.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1.0 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from March 15, 2023, through March 14, 2024:
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-078-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.